Has the Non-Resection Rate Decreased During the Last Two Decades among Patients Undergoing Surgical Exploration for Pancreatic Adenocarcinoma?

Catherine Mattevi  
Institut Paoli-Calmettes

Jonathan Gamier  
Institut Paoli-Calmettes

Ugo Marchese  
Institut Paoli-Calmettes

Jacques Ewald  
Institut Paoli-Calmettes

Marine Gilabert  
Institut Paoli-Calmettes

Flora Poizat  
Institut Paoli-Calmettes

Gilles Piana  
Institut Paoli-Calmettes

Jean-Robert Delpero  
Institut Paoli-Calmettes

Olivier Turrini (✉ turrinio@ipc.unicancer.fr)  
Institut Paoli-Calmettes  https://orcid.org/0000-0002-2144-2380

Research article

Keywords: pancreatic adenocarcinoma, CT, liver MRI, staging

DOI: https://doi.org/10.21203/rs.3.rs-33035/v2

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Purpose To determine if improvement in imaging reduces the non-resection rate (NRR) among patients with pancreatic ductal adenocarcinoma (PDAC). Methods From 2000 to 2019, 751 consecutive patients with PDAC were considered eligible for a intention-to-treat pancreatectomy and entered the operating room. In April 2011, our institution acquired a dual energy spectral computed tomography (CT) scanner and liver diffusion weighted magnetic resonance imaging (DW-MRI) was included in the imaging workup. We consequently considered 2 periods of inclusion: period #1 (February 2000–March 2011) and period #2 (April 2011–August 2019). Results All patients underwent a preoperative CT scan with a median delay to surgery of 18 days. Liver DW-MRI was performed among 407 patients (54%). Median delay between CT and surgery decreased (21 days to 16 days, P <.01), and liver DW-MRI was significantly most prescribed during period #2 (14% vs 75%, P <.01). According to the intraoperative findings, the overall NRR was 24.5%, and remained stable over the two periods (24% vs 25%, respectively). While vascular invasion, liver metastasis, and carcinomatosis rates remained stable, para-aortic lymph nodes invasion rate (0.4% vs 4.6%; P <0.001) significantly increased over the 2 periods. The mean size of the bigger extra pancreatic tumor significantly decrease (7.9mm vs 6.4mm ( P <.01), respectively) when the resection was not done. In multivariate analysis, CA 19-9<500U/mL ( P <.01), and liver DW-MRI prescription ( P <.01) favoured the resection. Conclusions Due to changes in our therapeutic strategies, the NRR did not decrease during two decades despite imaging improvement.

Background

When a solid pancreatic mass is detected, a triple-phase thoraco-abdominal computerized tomography (CT) scan has to be performed to precisely locate and measure the tumor, assess arterial and venous involvement, and detect distant visceral metastasis [1]. Improvement of CT performance could also help in the differential diagnosis of periampullary neoplasms [2] but does not replace endoscopic ultrasound (EUS) which completes this imaging work up by obtaining tissue samples via fine needle aspiration. In cases of pancreatic ductal adenocarcinoma (PDAC), pancreatectomy (with or without induction treatment depending on the tumor stage) is the pivotal point of curative treatment. However, in the late 90s, non-resection during laparotomy for pancreatectomy was common due to intraoperative findings (i.e. local invasion of major vasculature, carcinomatosis, and liver metastasis) [3].

During the last two decades, the performance of CT scan and liver diffusion weighted magnetic resonance imaging (DW-MRI) [4,5] have improved dramatically; consequently, the non-resection rate (NRR) is expected to decrease during this period because these improvements should make it possible to detect extrapancreatic lesions (especially liver metastases) of smaller sizes. However, at the same time, two crucial points might have counterbalanced the improved efficiency of preoperative imaging. First, positive frozen sections of para-aortic lymph nodes (PALNs) were recognized by several teams, including ours, as a “new” intraoperative contraindication to surgery in patients with PDAC [6,7]. Second, pancreatic surgeons push over the limits of resection with complex vascular reconstruction [8]; thus, exploratory
Laparotomy is frequently performed in locally advanced disease that finally results in more cases of non-resection according to intraoperative findings.

The present study sought to determine if the improvement in preoperative imaging over the past two decades have permitted a significant reduction in NRR among patients with PDAC eligible for pancreatectomy.

**Methods**

*Patient selection*

From February 1, 2000 to August 31, 2019, 751 consecutive patients with PDAC were considered eligible for intention-to-cure pancreatectomy after a multidisciplinary staff decision, and entered the operating room at Institut Paoli-Calmettes, Marseille, France. Data were entered anonymously prospectively into a clinical database (NCT02871336) and analyzed retrospectively. The study protocol was approved by the institutional review board of our hospital. No ethic approval / consent to participate was required for this retrospective observational anonymous series.

*Initial staging and decided strategy*

The initial staging consisted of a physical examination, thoraco-abdominal CT scan, and CA 19-9 serum level determination (after resolution of jaundice). In April 2011, our institution acquired a dual energy spectral CT scanner that was consequently a landmark between first and second generation CT scanners and also marked the inclusion of liver DW-MRI in the imaging workup of patients. Thus, we considered two periods of inclusion: period #1 (February 2000–March 2011) and period #2 (April 2011–August 2019). As the relevance of positron emission tomography is still under debate [9], it was only performed among patients included in clinical trials. Exploratory laparoscopy was not routinely performed at initial staging or preoperatively. Surgery was decided on by a multidisciplinary team according to patients’ performance statuses, imaging, and response to neoadjuvant treatment among cases of locally advanced tumor. Vascular invasion, carcinomatosis, and liver metastasis were never confirmed based on the findings of EUS but via imaging. Exploratory laparoscopy may have been performed prior to laparotomy among cases of suspected unproven metastatic disease in order not to exclude the patient from a potentially curative strategy. Laparoscopy was performed only to detect carcinomatosis or liver metastasis, and not to determine local vascular invasion. Consequently, all patients included in the present study had a negative exploratory laparoscopy if performed.

*Surgery*

Pancreatectomy was performed via a subcostal incision or laparoscopic approach according to the tumor site and surgeon preference. First, a thorough abdominal exploration was performed. Contraindications for resection were intraoperative histologically proven carcinomatosis, liver metastasis, or PALNs metastasis.[7] Invasion of the superior mesenteric artery, celiac axis, or hepatic artery were not
considered as contraindications to resection in highly selected cases (fit patients, objective response to induction treatment, long [>6 months] follow up without any metastasis detected, low (<500 IU/mL) [10] CA 19-9 serum level, and no neoadjuvant chemoradiation). Venous resection was performed as described previously.[8] Specimens were inked to facilitate margin assessment according to period of inclusion.[11] Adjuvant chemotherapy was administered to fit patients according to a multidisciplinary team decision.

**Study parameters**

Several variables were evaluated: age, sex, body mass index (BMI), CA 19-9 serum level (U/mL; at diagnosis and after jaundice resolution), biliary stenting, neoadjuvant treatment administration, delay (days) from CT scan to surgery, period of staging (i.e. period #1 or period #2), liver DW-MRI and positron emission tomography request, and exploratory laparoscopy prior to intention-to-treat surgery (with calculation of the median delay (days) between laparoscopy and surgery). In cases of intraoperative contraindication, the etiology (i.e. carcinomatosis, liver metastasis, vascular involvement, or PALNs invasion) and size (mm) of the largest extra pancreatic tumor were noted. Type of surgery (i.e. pancreaticoduodenectomy (PD), total pancreatectomy, or distal pancreatectomy), venous, and/or arterial resections, postoperative courses, pathologic findings (R1 resection was defined by tumor cells within 1mm to resection margin), and adjuvant treatment administration were also noted. Survivals were calculated from date of diagnosis until the date of death or the censor date (December 2019) for living patients.

**Statistical analysis**

Categorical variables were compared using Fisher's exact test or the chi-squared test, and continuous variables using the student’s t-test. Multivariate analysis was performed using stepwise logistic regression by integrating factors identified in the univariate analysis with \( P < .1 \). Survival analysis were performed according to the Kaplan-Meier method; survival curves were compared using the Wilcoxon test. Data analyses were performed using GraphPad Prism version 6 (GraphPad Software Inc., La Jolla, CA, USA) and SPSS® version 24 (SPSS Inc., Chicago, IL, USA). Analyses items with \( P < .05 \) were considered statistically significant.

**Results**

The characteristics of the 751 patients are summarized in Table 1. All patients underwent a preoperative CT scan with a median delay to surgery of 18 days (range 1-55). Liver DW-MRI was performed among 407 patients (54%). A neoadjuvant treatment was delivered in 337 patients (45%). Pancreaticoduodenectomy was the main type of surgery (51%); a venous resection was achieved in 159 patients (21%). According to the intraoperative findings, the NRR was 24.5% (184 patients). Causes for non-resection were vascular invasion (10%), liver metastasis (7%), carcinomatosis (5%), and PALNs invasion (3%). Among the patients who underwent a negative explorative laparoscopy (n=82) and who entered the operating room, 23 (28%) finally where not resected due to a contraindication founded during
laparotomy (median delay from laparoscopy to surgery: 18 days (range: 5-37)). In patients who underwent resection (n=567), overall morbidity and 30-days mortality rates were 49% and 4.2% respectively. Three hundred and fifty-two patients (62%) received an adjuvant treatment; the median overall survival rate was 36 months.
Table 1
Characteristics of the 751 patients who entered the operating room.

|                              |                  |
|------------------------------|------------------|
| Sex Ratio (M/F)              | 1.05 (384/367)   |
| Median Age (range)           | 67 (25–86)       |
| Mean BMI (± SD)              | 24.7 (± 4.35)    |
| Period (%)                   |                  |
| 1 (February 2000-March 2011) | 224 (30)         |
| 2 (April 2011-August 2019)   | 527 (70)         |
| Biliary Stenting (%)         | 418 (58%)        |
| Work up Imaging (%)          | 751 (100)        |
| CT-scan                      | 407 (54)         |
| Liver Magnetic Resonance Imaging | 69 (9)      |
| Positron Emission Tomography |                  |
| Median delay CT-Surgery (days) (range) | 18 (1–55) |
| Mean CA 19 – 9 serum level* (UI) (± SD)(after jaundice resolution) | 552 (± 1200) |
| Neoadjuvant Treatment (%)    | 337 (45)         |
| Explorative Laparoscopy (%)  | 82 (11)          |
| Type of Surgery (%)          | 184 (25)         |
| Exploration without Resection| 384 (51)         |
| Pancreaticoduodenectomy      | 146 (19)         |
| Distal Pancreatectomy        | 37 (5)           |
| Total Pancreatectomy         | 159 (21)         |
| Venous Resection             | 19 (2.4)         |
| Arterial Resection           | 43 (5.7)         |
| En-bloc Resection of Neighbours Organs |              |

(BMI: Body Mass Index; SD: Standard Deviation, * at diagnosis)
| Sex Ratio (M/F) | 1.05 (384/367) |
|----------------|---------------|
| **Reason of Non-resection (%)** | |
| Carcinomatosis | 35 (5) |
| Liver Metastasis | 49 (7) |
| Vascular Invasion | 75 (10) |
| Distant Lymph Node Invasion | 25 (3) |
| Mean Size of Extra Pancreatic Metastasis (mm) (± SD) | 7.5 (± 4.6) |

| **Morbidity (%)** | 279 (49) / 85 (15) |
|-------------------|---------------------|
| Resected patients (Overall / Grades 3 to 5 Clavien-Dindo) | 47 (8) |
| Hemorrhage | 108 (219) |
| Clinically Revelant Postoperative Pancreatic Fistula | 43 (8) |
| Reintervention | 33 (1.8) / 6 (3.2) |
| Non-resected patients (Overall / Grades 3 to 5 Clavien-Dindo) | |

| **30- / 90-days Mortality (%)** | 24 (4.2) / 30 (5.3) |
|---------------------------------|---------------------|
| Resected patients | 4 (2.2) / 10 (5.4) |
| Non-resected patients | |

| **Pathologic Findings** (Resected patients) | 205 (36) |
|--------------------------------------------|---------|
| T1/2 (%) | 362 (64) |
| T3/4 (%) | 13 (2–44) |
| Median Number of Lymph Nodes (range) | 329 (58) |
| N+ (%) | 258 (46) |
| R1 (%) | 385 (68) |
| Perineural Invasion (%) | |

| **Adjuvant Treatment (%)** (Resected patients) | 352 (62) |

(BMI: Body Mass Index; SD: Standard Deviation, * at diagnosis)

*Period #1 versus period #2 (Table 2)*
Table 2
Characteristics of the 751 patients who entered the operating room according to period of workup imaging.

|                                | Period 1 | Period 2 | P value |
|--------------------------------|----------|----------|---------|
| n                              | 256      | 495      | < 0.01  |
| Sex Ratio (M/F)                | 1.11     | 1.02     | 0.58    |
| Median Age (range)             | 67 (32–85) | 65 (25–86) | 0.19 |
| Mean BMI (± SD)                | 25.3 (± 4.64) | 24.4 (± 4.1) | 0.01 |
| Biliary Stenting (%)           | 118 (46) | 300 (61) | < 0.001 |
| Work up Imaging (%)            | 224 (100) | 527 (100) | 1       |
| CT-scan                        | 35 (14)  | 372 (75) | < 0.001 |
| Liver Magnetic Resonance Imaging | 7 (2.7)  | 62 (13)  | < 0.001 |
| Median delay CT-Surgery (days) (range) | 21 (1–55) | 16 (1–48) | < 0.001 |
| Mean CA 19 – 9 serum level* (UI) (± SD) (after jaundice resolution) | 552 (± 937) | 552 (± 1275) | 1 |
| Explorative Laparoscopy (%)    | 23 (9)   | 59 (12)  | 0.27    |
| Neoadjuvant Treatment (%)      | 118 (46) | 219 (44) | 0.64    |
| Type of Surgery (%)            | 61 (24)  | 123 (25) | 0.79    |
| Exploration without Resection | 152 (59) | 232 (47) | 0.001   |
| Pancreaticoduodenectomy        | 35 (14)  | 111 (22) | 0.005   |
| Distal Pancreatectomy          | 8 (3)    | 29 (6)   | 0.11    |
| Total Pancreatectomy           | 36 (14)  | 123 (25) | < 0.001 |
| Venous Resection               | 0        | 19 (4)   | < 0.001 |
| Arterial Resection             | 16 (6)   | 27 (5)   | 0.74    |
| En-bloc Resection of Neighbours Organs |         |          |         |

(BMI: Body Mass Index; SD: Standard Deviation, * at diagnosis)
| Reason of Non-resection (%) | Period 1 | Period 2 | P-value |
|----------------------------|----------|----------|---------|
| Carcinomatosis             | 15 (6)   | 20 (4)   | 0.28    |
| Liver Metastasis           | 12 (5)   | 37 (7)   | 0.16    |
| Vascular Invasion          | 33 (13)  | 42 (8)   | 0.07    |
| Total                      | 60 (23)  | 99 (20)  | 0.3     |
| Distant Lymph Node Invasion| 7.9 (± 5.2) | 6.4 (± 3.9) | <0.01 |

| Mean Size of Extra Pancreatic Metastasis (mm) (± SD) |
|-----------------------------------------------------|
| Period 1                                            |
| Carcinomatosis                                     | 15 (6)   |
| Liver Metastasis                                   | 12 (5)   |
| Vascular Invasion                                  | 33 (13)  |
| Total                                              | 60 (23)  |
| Distant Lymph Node Invasion                         | 7.9 (± 5.2) |

| Morbidity (%) (resected patients)                   |
|-----------------------------------------------------|
| Overall / Grades 3 to 5                             |
| Hemorrhage                                          |
| Clinically Revelevant Postoperative Pancreatic Fistula |
| Reintervention                                     |
| Mean                                                  |
| Period 1                                            |
| Period 2                                            |
| P-value                                              |
| 195                                                  |
| 372                                                  |
| 0.66 / 0.3                                           |
| 93 (48) / 28 (14)                                   |
| 186 (35) / 57 (15)                                  |
| 0.08                                                |
| 22 (11)                                              |
| 25 (11)                                              |
| 0.99                                                |
| 37 (19)                                              |
| 71 (13)                                              |
| 0.31                                                |
| 18 (9)                                               |
| 25 (4.7)                                             |

| 30- / 90-days Mortality (%) (resected patients) |
|------------------------------------------------|
| 11 (5.6) / 16 (8.2)                              |
| 13 (3.5) / 14 (3.8)                              |
| 0.27 / 0.03                                      |

| Pathologic Findings (resected patients)           |
|--------------------------------------------------|
| T1/2 (%)                                          |
| T3/4 (%)                                          |
| Median Number of Examined Lymph Nodes (range)     |
| N+ (%)                                            |
| R1 (%)                                            |
| Perineural Invasion (%)                           |
| Adjuvant Treatment (%) (resected patients)        |
| Mean                                              |
| Period 1                                          |
| Period 2                                          |
| P-value                                           |
| 71 (36)                                           |
| 134 (36)                                          |
| 0.74                                              |
| 124 (64)                                          |
| 238 (64)                                          |
| 0.93                                              |
| 10 (2–23)                                         |
| 15 (4–44)                                         |
| <0.01                                             |
| 99 (51)                                           |
| 230 (62)                                          |
| 0.01                                              |
| 61 (42)                                           |
| 177 (48)                                          |
| 0.18                                              |
| 63 (56)                                           |
| 263 (71)                                          |
| 0.06                                              |
| 91 (47)                                           |
| 261 (70)                                          |
| <0.001                                            |

| (BMI: Body Mass Index; SD: Standard Deviation, * at diagnosis) |

Table 3: Characteristics of the 751 patients who entered the operating room according to resection achievement.
|                     | Non Resected | Resected | P uni. | P multi (95%CI) |
|---------------------|--------------|----------|--------|----------------|
| n (%)               | 184 (25)     | 567 (75) | -      | -              |
| Sex Ratio (M/F)     | 1.45         | 1.09     | 0.08   | -              |
| Median Age (range)  | 66 (35-79)   | 65 (26-86)| 0.38  | -              |
| Mean BMI (±SD)      | 24.3 (±4.2)  | 24.7 (±4.67)| 0.16  | -              |
| Period (%)          |              |          | 0.51   | -              |
| 1 (February 2000-March 2011) | 56 (25) | 168 (75) |        |                |
| 2 (April 2011-August 2019)  | 128 (24) | 399 (76) |        |                |
| Work up Imaging (%) |              |          |        |                |
| CT-scan             | 184 (100)    | 567 (100)| 1      | <0.001         |
| Liver Magnetic Resonance Imaging | 73 (40) | 334 (59) | <0.01  | <0.01 (3.34 [2.24; 5.01]) |
| Positron Emission Tomography | 20 (11) | 49 (9) | 0.38   | -              |
| Median delay CT-Surgery (days) (range) | 18 (6-55) | 18 (1-43) | 0.29 | -              |
| Mean CA 19-9 serum level (UI) (±SD) | 848 (±1004) | 391(±852) | <0.01  | <0.01 (1.99 [1.21; 3.71])* |
| Explorative Laparoscopy (%) | 21 (11) | 61 (11) | 0.79   | -              |
| Neoadjuvant Treatment (%) | 70 (38) | 267 (47) | 0.033  | 0.17 (1.12 [0.91; 1.71]) |

(* in patients with CA 19-9 < 500UI/mL)

More patients underwent surgery during period #2 (224 versus (vs) 527; P<.001). Median delay between CT and surgery decreased (21 days to 16 days, P<.01), and liver DW-MRI was significantly most prescribed during period #2 (14% vs 75%, P<.01). While vascular invasion (13% vs 8%), liver metastasis (5% vs 7%), carcinomatosis (6% vs 4%) rates remained stable, PALNs invasion rate (0.4% vs 4.6%; P<.001) significantly increased over the 2 periods. In patients who underwent resection, postoperative courses were comparable for most criteria excepted for the 90-days mortality rate that decreased from 8.2% to 3.8% (P=.03), and for adjuvant treatment administration rate that increased from 47% to 70% (P<.001). Pathologic findings showed significantly more lymph node harvested (median number: 10 vs 15), and more lymph node invasion (51% vs 62%) during period #2 when comparing with period #1. Median overall survival time was higher during period#2 if patients benefit (30 vs 45 months; P<.01)(figure 1A) or not from resection (13 vs 16 months; P=.049)(figure 1B).
Non-resection rate

NRR were comparable between periods #1 and #2 (25% vs 24%, respectively), as well as if we focused in patients with resectable disease (i.e. who did not receive neoadjuvant treatment) at diagnosis (13% vs 18% (P=.07), respectively). Carcinomatosis, liver metastasis, and local vascular contraindication rates were stable when comparing periods #1 and #2 whereas PALNs invasion contraindication rate increased (0.3% vs 5% (P<.001), respectively); the mean size of the bigger extra pancreatic tumor significantly decrease (7.9mm vs 6.4mm (P<.01), respectively) when the resection was not done. In multivariate analysis, CA 19-9<500U/mL (P<.01), and liver DW-MRI prescription (P<.01) favoured the resection. When a liver DW-MRI was not achieved, the relative risk of non-resection was 1.8 (95% CI [1.43; 2.72].

Discussion

Our study revealed that the NRR did not decrease during the last 2 decades among patients with PDAC entering the operating room for an intention-to-cure pancreatectomy. The observed overall NRR of 24.5% was consistent with those of previously reported series among patients diagnosed with PDAC.[12]

Staging

There is no doubt that the technical performances of CT and DW-MRI have improved over the last 2 decades. As a surrogate of this enhancement, the sizes of the extra-pancreatic disease which contraindicate the resection significantly decreased in the second period. Moreover, vascular contact is certainly better assessed nowadays via imaging eventually associated to EUS [13], but these improvements were not correlated with a reduction in NRR, which was surprising. It is now well-known that a short (<30 days) delay between CT scan and surgery is crucial in order not to increase the NNR [14]. In our series, the majority of patients underwent a 3-phase CT scan with an “optimal” (18 days) delay [15-17] prior to surgery whatever the period of inclusion. This insured a relevant comparison between the two periods and the absence of NRR reduction could not be attributed to a higher delay between imaging and surgery in period #1 that counterbalanced the enhancement of imaging.

Routine laparoscopy was not performed, and this could be a drawback of our study; we suppose that any included patients could have been spared exploration if laparoscopy was performed. However, laparoscopy is not routinely performed worldwide and a recent large series reported that about 10% of patients underwent this procedure [18]. Similarly, its relevance remains under debate.[19] Nevertheless, we wanted to highlight that 12% of patients in our series who underwent an exploratory laparoscopy were finally found to have a contraindication to resection intraoperatively (with a “short” delay from laparoscopy to exploration of 18 days). This suggested that negative exploratory laparoscopy did not systematically imply a resection, mainly because it is difficult to explore major vasculature involvement in this way. As we strongly believe that positive PALNs are a contraindication to resection in patients with PDAC [7], we started a prospective evaluation of routine laparoscopy at diagnosis with PALN resection this year. This strategy will help assess the laparoscopic relevance at diagnosis, and we will report our results after the first 100 cases have been assessed.
Finally, the CA 19-9 serum level was independently associated with a higher NRR, reminding us the importance of the biological dimension in patients with PDAC [20, 21].

**Non-resection rate**

Not surprisingly, liver DW-MRI appeared to be a crucial tool for staging as already reported [4,22]. However, it could not be considered in isolation. Indeed, liver DW-MRI is a “focal” exam that only screens a specific zone (the liver and pancreas), has blind spots (subcapsular small liver metastasis and interference of duct dilation in case of bile duct obstruction) and consequently could not replace CT scan. To reinforce this, we showed that a CT/DW-MRI combination significantly reduced the NRR compared with patients who only underwent a CT scan (RR, 1.8). However, we did not observe a decrease in NRR between the two periods, despite a significantly higher liver MRI rate during period #2 among patients who did not have locally advanced disease at diagnosis. This could be a contradictory observation; however, two major changes in the patients’ strategies dramatically impacted period #2 at our institution and could explain the lack of reduction in NRR. First, we integrated the intraoperative PALNs assessment in our decision-making strategies for patients with PDAC scheduled for pancreatectomy. [6] Indeed, among cases with positive frozen section results, we did not perform tumor resection [7]. Thus, not surprisingly, we observed a significantly higher NRR rate due to PALNs invasion during period #2. However, this relevant difference was not sufficient to increase the overall NRR probably because very few patients presented with PALNs invasion (3%). Second, since 2010, pancreatic surgery was performed by a dedicated surgical team [8]. This increased both the number of cases and the complexity of the procedures performed. Consequently, we will have decreased the risk of achieving non-resection if our “local” criteria of resection had remained constant between the two periods. However, we pushed over the limits of resectability with venous and arterial resection [8] and this increased the risk of non-resection resulting in the absence of significant impact on the NRR.

Finally, we did not observe a reduction in NRR when considering patients with resectable disease at diagnosis. However, as the difference was not significant (due to an insufficient sample size), we noted a trend of NRR reduction between the two periods in this sub-population (13% vs 18%; \( P=.07 \)). By suppressing the potential bias due to local invasion, we could argue that CT/DW-MRI helped to better identify liver metastasis or carcinomatosis at staging among patients with resectable disease.

Our study was not designed to assess oncology outcomes. However, we observed encouraging changes in survival between the two periods, probably due to improvements in surgery and perioperative treatment.

**Perspectives**

Our study supported the notion that patients diagnosed with pancreatic PDAC must benefit from CT and liver DW-MRI. Inclusion of the CA 19-9 level and laparoscopy might also help to reduce the NRR and consequently spare the patient from useless exploratory surgery. In the future, imaging [23-25] development in association with EUS [26,27], and assistance during laparoscopy [28] could improve the
relevance of tumor staging. However, the aim of staging is to detect existing distant metastasis or vascular invasion that precludes resection. This concept will probably be challenged in the near future by new biomarkers such as circulating tumor cell number [29] or genomic assessment of the tumor [30,31] that could predict poor outcomes. If such staging became obvious and relevant, the pancreatic surgeon will then face a complex ethical situation: is a patient without any contraindication to resection based on the “classic” imaging staging to be spared resection because these new tools predict rapid disease progression?

Conclusion

Due to changes in our therapeutic strategies, the NRR did not decrease these last two decades despite imaging improvement. However, our study highlighted the crucial role of combining CT and DW-MRI to spare patients from surgical exploration.

Abbreviations

CT: computerized tomography
EUS: endoscopic ultrasound
PDAC: pancreatic ductal adenocarcinoma
DW-MRI: fusion weighted magnetic resonance imaging
NNR: non-resection rate
PALN: para-aortic lymph node

Declarations

- Ethics approval and consent to participate: no ethic approval or consent to participate was required for this retrospective observational anonymous series as consistent with national regulatory rules.
- Consent for publication: N/A
- Competing interests: None
- Funding: None
- Authors’ contributions:
  - Data acquisition: CM/OT
  - Data analysis: CM/JG/UM/JE
  - Manuscript drafting: all authors except OT
All authors have read and approved the final manuscript

Acknowledgements We would like to thank Editage (www.editage.com) for English language editing.

Availability of data and materials:

Data are available upon request from the corresponding author

References

1. Ducreux M, Cuhna AS, Caramella C et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v56-68. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma (Version 2. 2018).

2. Lu J, Hu D, Tang H et al. Assessment of tumor heterogeneity: Differentiation of periampullary neoplasms based on CT whole-lesion histogram analysis. Eur J Radiol. 2019 Jun;115:1-9.

3. Traverso LW. What are the problems associated with the surgical treatment of patients with pancreatic cancer? J Hepatobiliary Pancreat Surg. 1998;5(2):138-42.

4. Marion-Audibert AM, Vullierme MP, Ronot M et al. Routine MRI With DWI Sequences to Detect Liver Metastases in Patients With Potentially Resectable Pancreatic Ductal Carcinoma and Normal Liver CT: A Prospective Multicenter Study. AJR Am J Roentgenol. 2018 Nov;211(5):W217-W225.

5. Hayano K, Miura F, Wada K et al. Diffusion-weighted MR imaging of pancreatic cancer and inflammation: Prognostic significance of pancreatic inflammation in pancreatic cancer patients. Panreatology. 2016 Jan-Feb;16(1):121-6.

6. Schwarz L, Lupinacci RM, Svrcek M et al. Para-aortic lymph node sampling in pancreatic head adenocarcinoma. Br J Surg. 2014 Apr;101(5):530-8.

7. Marchese U, Ewald J, Gilabert M, Delpero JR, Turrini O. Outcomes of pancreatic adenocarcinoma that was not resected because of isolated para-aortic lymph node involvement. J Visc Surg. 2019 Apr;156(2):97-101.

8. Al Faraï A, Garnier J, Ewald J et al. International Study Group of Pancreatic Surgery type 3 and 4 venous resections in patients with pancreatic adenocarcinoma: the Paoli-Calmettes Institute experience. Eur J Surg Oncol. 2019 Jun 3.

9. Wartski M, Sauvanet A. 18F-FDG PET/CT in pancreatic adenocarcinoma: A role at initial imaging staging? Wartski M, Sauvanet A. Diagn Interv Imaging. 2019 Aug 8.

10. Isaji S, Mizuno S, Windsor JA et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Panreatology. 2018 Jan;18(1):2-11.

11. Menon KV, Gomez D, Smith AM, Anthoney A, Verbeke CS. Impact of margin status on survival following pancreateoduodenectomy for cancer: the Leeds Pathology Protocol (LEEP). HPB (Oxford).
12. van der Geest LGM, Lemmens VEPP, de Hingh IHJT et al. Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer. Br J Surg. 2017 Oct;104(11):1568-1577.

13. Du T, Bill KA, Ford J et al. The diagnosis and staging of pancreatic cancer: A comparison of endoscopic ultrasound and computed tomography with pancreas protocol. Am J Surg. 2018 Mar;215(3):472-475.

14. Al-Hawary MM, Francis IR, Chari ST et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology. 2014 Jan;270(1):248-60.

15. Healy GM, Redmond CE, Murphy S et al. Preoperative CT in patients with surgically resectable pancreatic adenocarcinoma: does the time interval between CT and surgery affect survival? Abdom Radiol (NY). 2018 Mar;43(3):620-628.

16. Sanjeevi S, Ivancics T, Lundell L et al. Impact of delay between imaging and treatment in patients with potentially curable pancreatic cancer. Br J Surg. 2016 Feb;103(3):267-75.

17. Glant JA, Waters JA, House MG et al. Does the interval from imaging to operation affect the rate of unanticipated metastasis encountered during operation for pancreatic adenocarcinoma? Surgery. 2011 Oct;150(4):607-16.

18. Paracha M, Van Orden K, Patts G, Tseng J, McAneny D, Sachs T. Opportunity Lost? Diagnostic Laparoscopy in Patients with Pancreatic Cancer in the National Surgical Quality Improvement Program Database. Paracha M, Van Orden K, Patts G, Tseng J, McAneny D, Sachs T. World J Surg. 2019 Mar;43(3):937-943.

19. Looijen GA, Pranger BK, de Jong KP, Pennings JP, de Meijer VE, Erdmann JL. The Additional Value of Laparoscopic Ultrasound to Staging Laparoscopy in Patients with Suspected Pancreatic Head Cancer. J Gastrointest Surg. 2018 Jul;22(7):1186-1192.

20. Petrushenko W, Gundara JS, De Reuver PR, O’Grady G, Samra JS, Mittal A. Systematic review of perioperative prognostic biomarkers in pancreatic ductal adenocarcinoma. HPB (Oxford). 2016 Aug;18(8):652-63.

21. Medrano J, Garnier J, Ewald J et al. Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma. Panreatology. 2020 Mar;20(2):223-228.

22. Bowman AW, Bolan CW. MRI evaluation of pancreatic ductal adenocarcinoma: diagnosis, mimics, and staging. Abdom Radiol (NY). 2019 Mar;44(3):936-949.

23. Nagayama Y, Tanoue S, Inoue T et al. Dual-layer spectral CT improves image quality of multiphasic pancreas CT in patients with pancreatic ductal adenocarcinoma. Nagayama Y, Tanoue S, Inoue T, Oda S, Nakaura T, Utsunomiya D, Yamashita Y. Eur Radiol. 2019 Jul 16.

24. Ebner M, Patel PA, Atkinson D et al. Super-resolution for upper abdominal MRI: Acquisition and post-processing protocol optimization using brain MRI control data and expert reader validation. Magn
Reson Med. 2019 Nov;82(5):1905-1919.

25. Wang S, Shi H, Yang F, Teng X, Jiang B. The value of 18F-FDG PET/CT and carbohydrate antigen 19-9 in predicting lymph node micrometastases of pancreatic cancer. Abdom Radiol (NY). 2019 Sep 30

26. Alberghina N, Sánchez-Montes C, Tuñón C et al. Endoscopic ultrasonography can avoid unnecessary laparotomies in patients with pancreatic adenocarcinoma and undetected peritoneal carcinomatosis. Pancreatology. 2017 Sep - Oct;17(5):858-864.

27. Newton AD, Predina JD, Shin MH et al. Intraoperative Near-infrared Imaging Can Identify Neoplasms and Aid in Real-time Margin Assessment During Pancreatic Resection. Ann Surg. 2019 Jul;270(1):12-20.

28. van Veldhuisen E, Walma MS, van Rijssen LB et al. Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study. HPB (Oxford). 2019 Apr 19. pii: S1365-182X(19)30102-9.

29. Tao L, Su L, Yuan C et al. Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer. Tao L, Su L, Yuan C, Ma Z, Zhang L, Bo S, Niu Y, Lu S, Xiu D. Cancer Manag Res. 2019 Aug 6;11:7405-7425.

30. González-Borja I, Viúdez A, Goñi S et al. Omics Approaches in Pancreatic Adenocarcinoma. Cancers (Basel). 2019 Jul 25;11(8).

31. Chang JC, Kundranda M. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma. Int J Mol Sci. 2017 Mar 20;18(3).

Figures
Figure 1

Survival in patients who benefit (1A) or not (1B) from resection according to period of surgery.